Drugs / Trivalent Salmonella Conjugate Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05525546 | Aug 2022 → Jun 2023 | — | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 1 | NCT03981952 | Oct 2019 → May 2021 | — | University of Maryland, Baltimore | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trivalent Salmonella Conjugate Vaccine | “Trivalent Salmonella Conjugate Vaccine (TSCV) consists of Vi capsule polysaccharide conjugated to tetanus toxoid and core-plus-O-polysaccharides from the two most prevalent...” PMID 41001453 ↗ Sep 2025 |
| Known as | TSCV | “Trivalent Salmonella Conjugate Vaccine (TSCV) consists of Vi capsule polysaccharide conjugated to tetanus toxoid and core-plus-O-polysaccharides from the two most prevalent...” PMID 41001453 ↗ Sep 20251“Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation” NCT05525546 ↗ |
| Modality | Vaccine | “Trivalent Salmonella Conjugate Vaccine (TSCV) consists of Vi capsule polysaccharide conjugated to tetanus toxoid and core-plus-O-polysaccharides from the two most prevalent...” PMID 41001453 ↗ Sep 2025 |
| Route | Intramuscular | “6.25 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.” NCT03981952 ↗ |